HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a collaboration with Censo Biotechnologies Ltd. ("Censo") to source and provide patient-derived induced pluripotent stem cells ("iPSC") to support Evotec's broad iPSC platform.
Censo will provide its sourcing and reprogramming technologies and expertise to create a high-quality, bespoke repository of hundreds of patient-derived iPS cell lines, covering multiple diseases with an initial focus on CNS diseases. The contract will run for an initial period of two years.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very pleased to have teamed up with Censo, a proven leader in the field of iPSCs - covering in particular the sourcing of donor cells, the generation of iPS cell lines as well as extensive characterisation and quality control. Their platform will support and complement Evotec's use of patient-derived disease models for drug screening and the discovery of more disease-relevant drug candidates."
Aidan Courtney, CEO of Censo Biotechnologies, added: "Both Censo and Evotec believe in the enabling power of patient-derived iPSCs as a drug discovery tool. This collaboration is a validation of Censo's extensive network, technology platform and expertise in this space. We look forward to working closely with our colleagues at Evotec and supporting their ambitious plans for iPSC-based drug discovery."
No financial details were disclosed.
Biotechnologies Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to create virtually any cell in the human body. By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population. The company was founded in 2016 through the merger of Roslin Cellab and Roslin Cell Sciences and has facilities in both Edinburgh and Cambridge, UK. www.censobio.com; Follow us on Twitter @Censobio.
About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
|Manfred Eigen Campus / Essener Bogen 7|
|Phone:||+49 (0)40 560 81-0|
|Fax:||+49 (0)40 560 81-222|
Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in